Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Maria Ochoa-De-Olza

Showing results (1-10 of 29) with videos related to

Pageof 3
Sort By:
Elife|September 24, 2021
A promising platform for predicting toxicityMaria Ochoa de Olza
Targeted Oncology|December 21, 2016
Immuno-Oncology: The Third Paradigm in Early Drug DevelopmentJuan Martin-Liberal, Cinta Hierro, Maria Ochoa de Olza, et al.
Seminars in Oncology|November 29, 2015
The Personalization of Therapy: Molecular Profiling Technologies and Their ApplicationJorge Zeron-Medina, Maria Ochoa de Olza, Irene Braña, et al.
Journal for Immunotherapy of Cancer|July 14, 2022
Low-dose irradiation for reversing immunotherapy resistance: how to translate?Maria Ochoa-de-Olza, Jean Bourhis, George Coukos, et al.
The Lancet. Oncology|March 31, 2022
Radiotherapy plus immune checkpoint blockade in PD(L)-1-resistant metastatic NSCLCMaria Ochoa-de-Olza, Jean Bourhis, George Coukos, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 31, 2011
Paraneoplastic opsoclonus-myoclonus syndrome as a new and single manifestation of relapsing disease in a patient with small cell lung cancerErnest Nadal, Jordi Bruna, Maria Ochoa de Olza, et al.
Current Opinion in Biotechnology|September 4, 2020
High versus low dose irradiation for tumor immune reprogrammingMaria Ochoa de Olza, Jean Bourhis, Melita Irving, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 24, 2019
Agnostic-Histology Approval of New Drugs in Oncology: Are We Already There?Cinta Hierro, Ignacio Matos, Juan Martin-Liberal, et al.
International Journal of Molecular Sciences|February 4, 2021
Tumor-Associated Microbiome: Where Do We Stand?Marc Oliva, Nuria Mulet-Margalef, Maria Ochoa-De-Olza, et al.
Human Gene Therapy|September 21, 2018
A Phase 1 Trial of Oncolytic Adenovirus ICOVIR-5 Administered Intravenously to Cutaneous and Uveal Melanoma PatientsMargarita García, Rafael Moreno, Marta Gil-Martin, et al.
Pageof 3

Showing results (1-10 of 29) with videos related to

Sort By:
Pageof 3
Elife|September 24, 2021
A promising platform for predicting toxicityMaria Ochoa de Olza
Targeted Oncology|December 21, 2016
Immuno-Oncology: The Third Paradigm in Early Drug DevelopmentJuan Martin-Liberal, Cinta Hierro, Maria Ochoa de Olza, et al.
Seminars in Oncology|November 29, 2015
The Personalization of Therapy: Molecular Profiling Technologies and Their ApplicationJorge Zeron-Medina, Maria Ochoa de Olza, Irene Braña, et al.
Journal for Immunotherapy of Cancer|July 14, 2022
Low-dose irradiation for reversing immunotherapy resistance: how to translate?Maria Ochoa-de-Olza, Jean Bourhis, George Coukos, et al.
The Lancet. Oncology|March 31, 2022
Radiotherapy plus immune checkpoint blockade in PD(L)-1-resistant metastatic NSCLCMaria Ochoa-de-Olza, Jean Bourhis, George Coukos, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 31, 2011
Paraneoplastic opsoclonus-myoclonus syndrome as a new and single manifestation of relapsing disease in a patient with small cell lung cancerErnest Nadal, Jordi Bruna, Maria Ochoa de Olza, et al.
Current Opinion in Biotechnology|September 4, 2020
High versus low dose irradiation for tumor immune reprogrammingMaria Ochoa de Olza, Jean Bourhis, Melita Irving, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 24, 2019
Agnostic-Histology Approval of New Drugs in Oncology: Are We Already There?Cinta Hierro, Ignacio Matos, Juan Martin-Liberal, et al.
International Journal of Molecular Sciences|February 4, 2021
Tumor-Associated Microbiome: Where Do We Stand?Marc Oliva, Nuria Mulet-Margalef, Maria Ochoa-De-Olza, et al.
Human Gene Therapy|September 21, 2018
A Phase 1 Trial of Oncolytic Adenovirus ICOVIR-5 Administered Intravenously to Cutaneous and Uveal Melanoma PatientsMargarita García, Rafael Moreno, Marta Gil-Martin, et al.
Pageof 3